What Ascend Advanced Therapies does

Ascend Advanced Therapies is a private gene-to-GMP contract development and manufacturing organization (CDMO) headquartered in Rockville, Maryland, with operating sites in Alachua, Florida and Munich, Germany. The company provides process development, analytical testing, GMP manufacturing, and aseptic fill-finish services for gene therapies (AAV and lentiviral vectors), oncolytics, vaccines, and immunotherapies, serving biotech, biopharma, and US government customers. Its differentiating technology is the proprietary EpyQ two-plasmid AAV production system, granted as European patent EP3722434 and defended at the EPO in October 2025, which reduces DNA cost and replication-competent AAV risk relative to traditional three-plasmid transfection. Ascend extends this platform with proprietary small-molecule enhancers delivering up to 3-fold AAV yield uplift, a microRNA screening service, and Oxford Nanopore-based long-read viral vector analytics.

The company operates 187,500+ SQFT of GMP and QC facilities across its three locations, with bioreactor capacity up to 500L, 60+ characterization assays, and in-house fill-finish capabilities at multiple US sites. Ascend generates revenue through project-based CDMO service contracts (professional services), licensing of the EpyQ platform to external manufacturers (with required Ascend-supplied GMP plasmid), sale of GMP plasmids to licensees, and ABL's legacy catalog products including p24 ELISA kits. Pricing is quote-based and not publicly disclosed. Customer segments are segmented horizontally across gene therapy developers, oncolytic and immunotherapy developers, US government and public health organizations (via ABL), and academic institutions (via Addgene-distributed EpyQ plasmids).

Ascend's growth posture is highly acquisitive and capacity-driven: the company acquired GMP capacity from Beacon Therapeutics in April 2024 and integrated ABL, Inc. via a partnership with EW Healthcare Partners in November 2024, supported by an approximately $130.6 million exempt securities offering. Leadership is heavily Catalent-pedigreed (CEO Alessandra Rispoli, CFO Sharad Dubey, Board Chair John Chiminski, Director Karen Flynn), with CCO Seiga Ohmine and SVP of Global Business Development Patrick Lansky joining from WuXi Advanced Therapies and SK pharmteco/Cobra Biologics, respectively. The investor syndicate includes EW Healthcare Partners, Abingworth, Monograph Capital, Petrichor Healthcare Capital Management, DCVC Bio, 4BIO Capital, Cathay Health, Ajinomoto, Deerfield Management, Digitalis Ventures, and Lingotto Horizon.

Name

Ascend Advanced Therapies

Legal name

Ascend Advanced Therapies Ltd.

Website

https://ascend-adv.com

Company type

Private

Founded year

2023

Operating status

Operating

Headcount range

51–100 employees

Short description

Ascend Advanced Therapies is a private gene-to-GMP CDMO providing process development, manufacturing, analytics, and fill-finish for AAV, lentiviral, oncolytic, vaccine, and immunotherapy developers, anchored by its proprietary EpyQ two-plasmid AAV production system and operating 187,500+ SQFT across Rockville, Alachua, and Munich.

Ownership category

akta.pro rank

Product category

Biopharmaceutical Contract Development and Manufacturing (CDMO) Services

NAICS

Scientific Research and Development Services (5417), Research and Development in Biotechnology (except Nanobiotechnology) (541714), Pharmaceutical and Medicine Manufacturing (3254), Pharmaceutical Preparation Manufacturing (325412)

SIC

Services-Commercial Physical & Biological Research (8731), Pharmaceutical Preparations (2834), Biological Products, (No Disgnostic Substances) (2836)

akta.pro primary industry

Gene Therapy (Viral Vector/Plasmid) CDMO (HLAGABAE)

akta.pro secondary industries

Gene Therapy CMC/Process Development Platforms (capsid engineering, producer cell lines, plasmids, upstream/downstream) (HLAAACAN), Sterile Fill-Finish & Aseptic Manufacturing CDMO (HLAGABAH), Clinical Trial Material (CTM) Manufacturing & Supply CDMO (HLAGABAK), Oncology Gene Therapies (incl. oncolytic vectors & gene-modified approaches) (HLAAACAF)

Keywords

• Viral vector manufacturing
• Gene therapy CDMO
• AAV production services
• GMP contract manufacturing
• Aseptic fill-finish services

Headquarters

HQ city

Alachua

HQ country

United States

HQ region

North America

Offices3 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Infrastructure, Technology or R&D, Marketing or Sales, Supply Chain

Revenue model

1. Contract Development and Manufacturing (CDMO) Services: Full-service contract manufacturing organization providing process development, GMP manufacturing, analytical testing, and fill-finish services for gene therapies, oncolytics, vaccines, and immunotherapies. Revenue generated through project-based contracts and service agreements with biotech and pharma companies. Services span from early-stage development through commercial production.
2. EpyQ® Technology Licensing: Licensing of proprietary EpyQ® two-plasmid AAV production system to clients manufacturing outside Ascend facilities. Clients manufacturing at Ascend in Munich or Alachua do not require a license. External licensees pay annual license fee and must use Ascend's AdHelper/rep GMP plasmid under supply agreements. No milestones or royalties. License is transferable under same terms.
3. GMP Plasmid Supply: Supply of GMP-grade AdHelper/rep plasmid to EpyQ® licensees under supply agreements. EpyQ® licensees must source this plasmid exclusively from Ascend.
4. ABL Products (ELISA Kits, Cell Banking): Sale of ABL products including p24 ELISA kits (originally developed for HIV titer determination, now used for lentiviral vector titer quantification) and cell/virus banking services. Products sold off-the-shelf or as custom services.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels6 records

Core offering

Ascend Advanced Therapies is a gene-to-GMP contract development and manufacturing organization (CDMO) that delivers process development, GMP manufacturing, analytical testing, and aseptic fill-finish services for AAV gene therapies, lentiviral vectors, oncolytics, vaccines, and immunotherapies. Its offering is anchored by the proprietary EpyQ® two-plasmid AAV production system and 187,500+ SQFT of GMP facility footprint across Rockville MD, Alachua FL, and Munich Germany, with bioreactor scales up to 500L.

Product overview

Ascend Advanced Therapies is a gene-to-GMP contract development and manufacturing organization (CDMO) specializing in advanced therapy development and manufacturing. The company offers a unified platform combining proprietary technologies with comprehensive manufacturing services. Core offerings include the EpyQ® AAV Production System (a proprietary two-plasmid transfection platform), proprietary AAV production enhancers, and microRNA screening services. These are supported by GMP manufacturing capacity across three global facilities in Rockville, Maryland (72,000+ SQFT), Alachua, Florida (58,500+ SQFT), and Munich, Germany (57,000 SQFT). The company provides integrated services including process development, analytics and GMP QC testing, potency assay services, gene therapy formulation, and aseptic fill-finish operations. Additional products include the ABL p24 ELISA Kit for lentiviral vector titer determination and Viral Vector Long-Read NGS service using Oxford Nanopore sequencing.

Differentiator

Problem solved

Functional benefit

Brands

• EpyQ® AAV Production System: Proprietary two-plasmid transfection platform for AAV production that lowers cost and complexity compared to traditional three-plasmid systems.
• ABL Bio

Products and services

• Gene-to-GMP CDMO Services (Process Development, GMP Manufacturing, and Fill-Finish) End-to-end contract development, GMP manufacturing, and aseptic fill-finish services for gene therapies, oncolytics, vaccines, and immunotherapies. Includes upstream cell culture growth and production optimization, downstream purification, analytical development, tech transfer, and fill-finish for clinical through commercial supply. Targeted at biotech, biopharma, and government customers developing advanced therapies.
• EpyQ® AAV Production System (Two-Plasmid Transfection Platform with Technology Licensing) Proprietary two-plasmid AAV production system using one custom plasmid and one off-the-shelf plasmid that lowers DNA costs, reduces replication-competent AAV risk, and improves yields versus three-plasmid systems. Available to clients manufacturing at Ascend's Munich and Alachua facilities without a license; external manufacturers pay an annual license fee and must source Ascend's GMP AdHelper/rep plasmid under supply agreements. Protected by European patent EP3722434.
• Proprietary AAV Production Enhancers Two proprietary small-molecule enhancers that improve AAV vector yields (up to 3-fold with EpyQ® in Ambr15, up to 1.7-fold for 3-plasmid systems, up to 2.4-fold at Ambr250 scale and 5L bioreactors) without compromising quality attributes. Available as an add-on for Ascend's process development and GMP manufacturing services.
• microRNA Screening Service for AAV Production Enhancement Screening service identifying microRNAs (such as hsa-miR-125a-5p) that significantly enhance AAV vector productivity in HEK293 cells without compromising quality attributes, enabling the development of engineered HEK293 producer cell lines for more efficient AAV production. Offered as part of Ascend's platform innovation service line.
• Viral Vector Long-Read NGS Service Oxford Nanopore-based long-read sequencing service for AAV and other viral vectors providing complete impurity and integrity profiling. Detects truncations, backbone carryover, rep/cap fragments, host-cell DNA, and other unexpected impurities. Requires minimal material (~5E9 vg minimum), 15–20 business day turnaround, and is offered as part of Ascend's analytics and GMP QC testing portfolio.
• Aseptic Fill-Finish Services GMP aseptic filling operations for clinical trial materials including vialing, inspection, labeling, testing, storage, and distribution. Includes automated Flexicon FPC50W filling (up to 3,000 vials per batch) and the AST GENiSYS C system with 60-minute cycle times and pre-sterilized, ready-to-use containers. Available to gene therapy and advanced therapy developers at Ascend's US sites.
• Analytics & GMP QC Testing Services GMP-compliant analytical testing using 60+ state-of-the-art characterization and release assays covering Critical Quality Attributes including residual DNA, endotoxin, subvisible particles, capsid concentration, potency, and vector genome integrity. Uses ddPCR and automated immunoassay. Includes GMP QC release testing and lot release for Phase I/II clinical products.
• Potency Assay Services for Advanced Therapies Development, qualification, and validation of mechanism-driven potency assays for gene therapies and ATMPs. Includes assay strategy, non-GMP qualification, ICH-compliant GMP validation, lifecycle support, and advanced statistical approaches (full-curve and linear-range PLA, factor-to-reference). Addresses non-ideal dose-response behavior, batch-to-batch variability, and low transduction efficiency.
• Gene Therapy Formulation Services High-throughput and focused formulation screening for AAV products. Includes pre-formulation assessments, advanced formulation development, stability testing, device compatibility studies, and optimization of low-concentration surfactants to reduce vector loss in convection-enhanced delivery for CNS administration.
• ABL p24 ELISA Kit Off-the-shelf ELISA kit for quantification of lentiviral vector titers, originally developed for HIV titer determination and adapted for cell and gene therapy applications. Sensitivity of 3–100 pg/mL with results in under 3 hours. Sold via the ABL Bio catalog.

Quantifiable outcome

• Up to 3-fold increase in AAV yields with proprietary enhancers using EpyQ® in Ambr15 bioreactors
• +6 more outcomes

Segments4 records

Ideal customer profiles4 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature8 records

Partnerships

Nine partnerships are on record, tiered notable and core.

• Oxford Nanopore TechnologiesnotableTechnology or Integration · 24 November 2025Ascend scientists participated in a recorded webinar hosted by Oxford Nanopore Technologies discussing implementation of Oxford Nanopore sequencing for AAV vector characterization. Ascend offers Viral Vector Long-Read NGS service using Oxford Nanopore technology for comprehensive impurity and integrity profiling.
• Sartorius Stedim BiotechnotableTechnology or Integration · 1 August 2025Ascend collaborated with Sartorius on AAV scalability demonstration using Sartorius bioreactors. Published white paper on 'Scaling AAV Production: Transitioning From 250mL to 200L' using Ambr® 250 Modular, Univessel® SU, Univessel® Glass, and Biostat STR® bioreactors. Sartorius collaboration on application notes for AAV filtration using Sartoclear Dynamics® Lab.
• John ChiminskicoreOthers · 5 March 2025John Chiminski appointed as Chair of Ascend's Board of Directors. Former CEO of Catalent (2009-2023) where he grew it into a global Tier 1 CDMO. Currently Senior Advisor for Abingworth and board member for QuidelOrtho. Brings three decades of leadership in healthcare and pharma services.
• Karen FlynncoreOthers · 5 March 2025Karen Flynn appointed as Independent Director on Ascend's Board, designated by EW Healthcare Partners. Former President of BioModalities at Catalent, Chief Commercial Officer and President of Biologics at Catalent, and Senior Vice President at West Pharmaceutical Services. Serves on boards of Quanterix, Sotera Health, Stevanato Group, and Germfree.
• Biberach University of Applied SciencesnotableStrategic or Co-development Partner · 1 January 2025Ascend collaborated with Prof. Kerstin Otte's research group at Biberach University for microRNA screening research. Biberach University is described as world-leading experts in microRNA field. Research collaboration led to identification of microRNAs enhancing AAV production (published in New Biotechnology, 2025).
• AddgenenotableChannel Partner/ Reseller/ Distributor · 1 January 2025EpyQ® AAV Production System plasmids made available through Addgene, the world's leading nonprofit plasmid repository. Addgene's mission is to accelerate research and discovery by improving access to useful, high-quality research materials. This partnership makes EpyQ® accessible to academic and non-profit researchers worldwide.
• ABL, Inc.coreStrategic or Co-development Partner · 12 November 2024Advanced BioScience Laboratories (ABL) became part of Ascend Advanced Therapies through the EW Healthcare Partners partnership. ABL brings over 60 years of experience in custom biologics and vaccines, GMP manufacturing for viral vectors, fill-finish capabilities, and strong government contract relationships. ABL operates from Rockville MD and Strasbourg, France. The ABL brand and website (ablinc.com) remain intact.
• AST, Inc.notableTechnology or Integration · 4 October 2024AST (AST, Inc.) partnered with Ascend to place a next-generation GENiSYS C fill-finish system at Ascend's Alachua, Florida GMP facility. This innovative filling technology offers robotic tub handling, fully automated filling and closing process, and 60-minute cycle times. System configuration customizable to customer needs with pre-sterilized, ready-to-use containers.
• Beacon TherapeuticsnotableStrategic or Co-development Partner · 9 April 2024Ascend acquired GMP manufacturing capacity from Beacon Therapeutics in Alachua, Florida in April 2024. The acquisition included 50L GMP AAV production capacity, process and analytical development services, and a team of employees transferred in with no gaps in coverage for existing and new production. The facility is undergoing expansion to become a multi-product commercial-grade facility.

Scale indicators6 records

Recent moves11 records

Expansion highlights7 records

Direct peers

• AGC Biologics: AGC Biologics is a global CDMO offering viral vector, cell therapy, and biologics GMP manufacturing with sites in the US, Europe, and Asia. It directly competes with Ascend in AAV and lentiviral CDMO services for advanced therapy sponsors.
• Catalent (Novo Holdings): Catalent is a Tier 1 global CDMO with a dedicated Cell & Gene Therapy business offering AAV/lentiviral process development, GMP manufacturing, and fill-finish across multiple sites. It is the most direct competitor given Ascend's CEO, Board Chair, and CFO all came from Catalent's C&GT business and pursue similar sponsors.
• Ajinomoto Bio-Pharma Services: Ajinomoto Bio-Pharma Services is a CDMO offering process development and GMP manufacturing for viral vectors, gene therapies, and complex biologics. It is both a direct competitor and an Ascend investor, and Ascend's CCO Seiga Ohmine previously held executive roles there.
• WuXi Advanced Therapies: WuXi ATU is one of the largest pure-play cell and gene therapy CDMOs with end-to-end AAV and lentiviral capabilities across the US and Europe. It is the largest direct competitor in the AAV CDMO space, and Ascend's new CCO Seiga Ohmine was previously at WuXi.
• SK pharmteco (Cobra Biologics): SK pharmteco's Cobra Biologics unit specializes in viral vector and plasmid DNA CDMO services for gene therapy and vaccine developers. It directly competes in the AAV and lentiviral manufacturing niche where Ascend operates, and Ascend's SVP Patrick Lansky previously held senior roles there.

Broad incumbents

• Lonza Cell & Gene: Lonza is a global Tier 1 CDMO with a substantial cell and gene therapy offering including AAV, lentiviral, and CAR-T manufacturing across multiple GMP sites in the US and Europe. It is a broad incumbent competing for the same enterprise gene therapy sponsors at greater scale.
• Samsung Biologics: Samsung Biologics is a large-scale biologics CDMO expanding into cell and gene therapy services through its Samsung Bioepis and planned gene therapy investments. It is a broad incumbent whose capital base and global reach position it as a long-term competitor.
• Thermo Fisher Scientific (Patheon): Thermo Fisher's pharma services division offers viral vector and biologics CDMO capabilities alongside its broader contract development and manufacturing portfolio. It competes for enterprise gene therapy sponsors at much greater scale and geographic breadth.
• Boehringer Ingelheim BioXcellence: Boehringer Ingelheim BioXcellence is the biopharma contract manufacturing arm of Boehringer Ingelheim, offering viral vector and cell therapy CDMO services including AAV. It is a broad incumbent competitor in gene therapy manufacturing.

Emerging players

• Aldevron (Danaher): Aldevron, now part of Danaher, manufactures plasmid DNA, mRNA, and proteins used in gene therapy and vaccine production. It is a partial competitor as a key input supplier (plasmids) into AAV CDMO workflows that Ascend's EpyQ® licensing and plasmid supply business targets.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat7 records

Key risks6 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/ascend-advanced-therapies

Compliance2 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles7 records

Subsidiaries2 records

Funding overview

Funding rounds2 records

Investors2 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Ascend Advanced Therapies